---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095072"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:08:25.240079+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coya Q2 net loss $2.9M; FDA demands more data before COYA 302 ALS Phase 2

## Summary
- Net loss $2.9M vs $3.1M YoY; collaboration rev $3.4M from Dr. Reddy's.
- Cash $36.6M at June 30, 2024.
- FDA requires additional non-clinical data before Phase 2 of COYA 302 in ALS; Coya plans to discuss in Q4 2024.
- Received $5M strategic investment from ADDF for COYA 302 in FTD.
- R&D expenses $4.6M (up from $1.1M) driven by preclinical costs for COYA 302.

## SEC filing metadata
- accession: 0000950170-24-095072
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017024095072/0000950170-24-095072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017024095072/coya-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095072
- JSON: https://secwatch.observer/filing/0000950170-24-095072.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.